Tech Company Financing Transactions
Immunitas Therapeutics Funding Round
Immunitas Therapeutics, operating out of Waltham, secured $58 million from Agent Capital, Alexandria Venture Investments and BrightEdge.
Transaction Overview
Company Name
Announced On
8/19/2021
Transaction Type
Venture Equity
Amount
$58,000,000
Round
Series B
Investors
Proceeds Purpose
The Series B funding will be used to advance Immunitas' lead program, IMT-009, a CD161 inhibitor, into the clinic to treat both solid tumors and hematological malignancies.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
830 Winter St. 2nd floor
Waltham, MA 02451
USA
Waltham, MA 02451
USA
Phone
Undisclosed
Website
Email Address
Overview
Immunitas is unlocking human immunology using novel single cell analyses to develop targeted therapeutics for patients with challenging, complex cancers.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Jeffrey Goldberg
Co-Founder
Lea Hachigian
Co-Founder
Christopher Westphal
VP - Bus. Development
Amanda Wagner
Browse more venture capital transactions:
Prev: 8/19/2021: Stacker venture capital transaction
Next: 8/19/2021: Apeel Sciences venture capital transaction
Share this article
About Database of VC Transactions
We do our best to record every notable VC transaction. VC investment data records on this site are sourced from company press releases and news coverage. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs